IL219264A0 - Docetaxel formulations with lipoic acid - Google Patents

Docetaxel formulations with lipoic acid

Info

Publication number
IL219264A0
IL219264A0 IL219264A IL21926412A IL219264A0 IL 219264 A0 IL219264 A0 IL 219264A0 IL 219264 A IL219264 A IL 219264A IL 21926412 A IL21926412 A IL 21926412A IL 219264 A0 IL219264 A0 IL 219264A0
Authority
IL
Israel
Prior art keywords
lipoic acid
docetaxel formulations
docetaxel
formulations
lipoic
Prior art date
Application number
IL219264A
Other languages
English (en)
Original Assignee
Scidose Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/589,145 external-priority patent/US8541465B2/en
Application filed by Scidose Llc filed Critical Scidose Llc
Publication of IL219264A0 publication Critical patent/IL219264A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL219264A 2009-10-19 2012-04-18 Docetaxel formulations with lipoic acid IL219264A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/589,145 US8541465B2 (en) 2009-10-19 2009-10-19 Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US12/721,563 US7772274B1 (en) 2009-10-19 2010-03-11 Docetaxel formulations with lipoic acid
PCT/US2010/040915 WO2011049650A1 (en) 2009-10-19 2010-07-02 Docetaxel formulations with lipoic acid

Publications (1)

Publication Number Publication Date
IL219264A0 true IL219264A0 (en) 2012-06-28

Family

ID=42536528

Family Applications (1)

Application Number Title Priority Date Filing Date
IL219264A IL219264A0 (en) 2009-10-19 2012-04-18 Docetaxel formulations with lipoic acid

Country Status (7)

Country Link
US (1) US7772274B1 (US07772274-20100810-C00002.png)
EP (1) EP2490638A1 (US07772274-20100810-C00002.png)
KR (1) KR20120108972A (US07772274-20100810-C00002.png)
AU (1) AU2010308497A1 (US07772274-20100810-C00002.png)
CA (1) CA2778231A1 (US07772274-20100810-C00002.png)
IL (1) IL219264A0 (US07772274-20100810-C00002.png)
WO (1) WO2011049650A1 (US07772274-20100810-C00002.png)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9839667B2 (en) * 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8476310B2 (en) * 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) * 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
PE20121429A1 (es) 2009-10-29 2012-11-06 Aventis Pharma Sa Nuevo uso antitumoral de cabazitaxel
LT2528602T (lt) 2010-01-28 2017-02-27 Eagle Pharmaceuticals, Inc. Bendamustino kompozicijos
EP2827862B1 (en) 2012-03-20 2023-12-27 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
PT3533447T (pt) 2012-03-20 2023-05-17 Eagle Pharmaceuticals Inc Composições líquidas de bendamustina para utilização num método de tratamento de condições com resposta a bendamustina em pacientes que requerem volumes reduzidos para administração
ES2732377T3 (es) * 2012-09-17 2019-11-22 Pfizer Procedimiento de preparación de nanopartículas terapéuticas
KR20140147336A (ko) * 2013-06-19 2014-12-30 에스케이케미칼주식회사 도세탁셀을 함유하는 액상 주사용 조성물
KR102307175B1 (ko) 2013-09-16 2021-10-01 아스트라제네카 아베 치료용 중합체 나노입자 및 이의 제조 방법과 사용 방법
CN105395477A (zh) * 2015-11-26 2016-03-16 李宏 一种多西他赛注射液及其制备方法
IT202000009577A1 (it) 2020-04-30 2021-10-30 Fatro Spa Formulazioni iniettabili di acido lipoico per il trattamento dello stress ossidativo e delle alterazioni metaboliche

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
FR2678833B1 (fr) 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US20070122465A1 (en) 1993-02-22 2007-05-31 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6395770B1 (en) 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US20030087954A1 (en) 1997-01-07 2003-05-08 Sonus Pharmaceuticals, Inc. Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
US6727280B2 (en) 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US20030105156A1 (en) 1997-01-07 2003-06-05 Nagesh Palepu Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
DE69804624T2 (de) 1997-07-29 2002-09-19 Upjohn Co Selbstemulgierende formulierung enthaltend lipophile verbindungen
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
US7030155B2 (en) 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6071952A (en) 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
KR20020059415A (ko) 1999-09-27 2002-07-12 스티븐 씨. 큐웨이 토콜-가용성 치료요법제
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
AU2001247726A1 (en) 2000-03-24 2001-10-08 Baker Norton Pharmaceuticals, Inc. Taxane-based compositions and methods of use
KR20020013174A (ko) 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
WO2002026208A2 (en) 2000-09-27 2002-04-04 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
AU1987802A (en) 2000-11-29 2002-06-11 Lyotropic Therapeutics Llc Solvent systems for pharmaceutical agents
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP1258243A1 (en) 2001-05-16 2002-11-20 N.V. Nutricia Lipoic acid for suppressing undesired haematological effects of chemotherapy and/or radiotherapy
US20040022820A1 (en) 2001-11-28 2004-02-05 David Anderson Reversed liquid crystalline phases with non-paraffin hydrophobes
CN1615130A (zh) 2001-12-28 2005-05-11 Ivax研究公司 基于紫杉烷的组合物及使用方法
JP2005523295A (ja) 2002-03-01 2005-08-04 ノバガリ、ファルマ、エスアー 難溶性薬剤の自己乳化型薬物送達システム
ES2685436T3 (es) 2002-12-09 2018-10-09 Abraxis Bioscience, Llc Composiciones y procedimientos para administración de agentes farmacológicos
US20040127551A1 (en) 2002-12-27 2004-07-01 Kai Zhang Taxane-based compositions and methods of use
WO2005016872A1 (en) 2003-06-11 2005-02-24 Novacea, Inc. Treatment of lung cancer with active vitamin d compounds in combination with other treatments
US20050119340A1 (en) 2003-06-13 2005-06-02 David Anderson Treatment methods with low-dose, longer-acting formulations of local anesthetics and other agents
WO2005003100A2 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
EP1510206A1 (en) 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
DE602004014624D1 (de) 2003-08-29 2008-08-07 Yissum Res Dev Co Selbst-nanoemulgierende ölige formulierung zur verabreichung von schwer wasserlöslichen arzneimitteln
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
US20050148534A1 (en) 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
WO2005035003A2 (en) 2003-09-22 2005-04-21 Dihedron Corporation Compositions and methods for increasing drug efficiency
US20050090551A1 (en) 2003-10-27 2005-04-28 Board Of Trustees Of Southern Illinois University Therapeutic use of methionine for the treatment or prevention of mucositis
CA2543722C (en) 2003-10-29 2011-01-04 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
KR20050099311A (ko) 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
US20060003976A1 (en) 2004-06-04 2006-01-05 Yuehua Zhang Cholesterol/bile acid/bile acid derivative-modified therapeutic drug compounds
US20070244114A1 (en) 2004-07-06 2007-10-18 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
KR20070059072A (ko) 2004-07-28 2007-06-11 에스디 파마슈티칼스 인코포레이티드 알파 토코페릴 석시네이트, 이의 동족체 및 이의 염의안정한 주사용 조성물
ZA200706530B (en) 2005-02-09 2009-01-28 Arqule Inc Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
JP2008530122A (ja) 2005-02-14 2008-08-07 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド Ｃ１０シクロプロピルエステル置換タキサン組成物
CA3054535A1 (en) 2005-02-18 2006-08-24 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
MX2007010394A (es) 2005-02-24 2008-02-19 Elan Pharma Int Ltd Formulaciones nanoparticuladas de docetaxel y analogos del mismo.
CA2611592A1 (en) 2005-06-17 2006-12-21 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
GB0517092D0 (en) 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
CN101291659A (zh) 2005-08-31 2008-10-22 阿布拉科斯生物科学有限公司 包含水难溶性药剂和抗微生物剂的组合物
NZ592132A (en) 2005-08-31 2012-12-21 Abraxis Bioscience Llc Composition comprising nanoparticles of docitaxel and a citrate
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070128289A1 (en) 2005-12-07 2007-06-07 Zhao Jonathon Z Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases
WO2007075825A2 (en) 2005-12-20 2007-07-05 Sonus Pharmaceuticals, Inc. Lipophilic anticancer drug compounds
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
WO2007109178A2 (en) 2006-03-16 2007-09-27 Pharmacyclics, Inc. Indole derivatives as inhibitors of histone deacetylase
WO2008026048A2 (en) 2006-08-31 2008-03-06 Wockhardt Research Centre Stable injectable pharmaceutical compositions of docetaxel
WO2008042841A2 (en) 2006-10-02 2008-04-10 Dr. Reddy's Laboratories Limited Docetaxel compositions
KR20090094811A (ko) 2006-10-05 2009-09-08 파나세아 바이오테크 리미티드 새로운 형태의 주입형 데포조성물 및 이를 조제하기 위한 방법
NZ581589A (en) 2007-06-22 2012-10-26 Scidose Llc Solubilized sterile injectable formulation of docetaxel without Tween 80
EP2278963A4 (en) 2008-01-16 2014-09-17 Anwar Rayan TAXOL DERIVATIVES AND CLOSELY RELATED COMPOUNDS
KR20100121505A (ko) 2008-03-07 2010-11-17 싸이도우스 엘엘씨. 플배스트랜 제제
CA2718567A1 (en) 2008-03-31 2009-12-03 Florida State University Research Foundation, Inc. C(10) ethyl ester and c(10) cyclopropyl ester substituted taxanes
KR20100018741A (ko) 2008-08-07 2010-02-18 신풍제약주식회사 도세탁셀 함유 항암용 주사제 조성물
US7772274B1 (en) * 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid

Also Published As

Publication number Publication date
KR20120108972A (ko) 2012-10-05
AU2010308497A1 (en) 2012-05-17
EP2490638A1 (en) 2012-08-29
CA2778231A1 (en) 2011-04-28
US7772274B1 (en) 2010-08-10
WO2011049650A1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
IL219264A0 (en) Docetaxel formulations with lipoic acid
ZA201106050B (en) Dye-polymers formulations
SI2389375T1 (sl) Derivati hidroksamske kisline
SI2637710T1 (sl) Formulacije na osnovi hialuronske kisline
IL269369A (en) The vehicles are improved
GB0919210D0 (en) Formulations
IL210600A0 (en) Kite based platform
ZA201300194B (en) Formulations
GB201110193D0 (en) Formulations
GB201013513D0 (en) Formulations
ZA201300098B (en) Pharmaceutical composition with enhanced solubility characteristics
ZA201300196B (en) Formulations
IL217390A0 (en) Formulations
GB201113974D0 (en) Stable vitamin c formulations
GB0917744D0 (en) Formulations
GB201018645D0 (en) Formulations
GB201018648D0 (en) Formulations
GB201018647D0 (en) Formulations
GB201018649D0 (en) Formulations
GB201012589D0 (en) Formulations
GB201010494D0 (en) Formulations
GB201008470D0 (en) Formulations
GB201008358D0 (en) Formulations
GB201007959D0 (en) Formulations
GB201007702D0 (en) Formulations